On this page
Mark Froimson
Insider
First SEC filing: June 12, 2026 · Latest: June 12, 2026
Insider at
Insider transactions
0 buys (P)
1 sells (S)
Net: $-10,905
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 10, 2026 | PCRX | A | 10,891 | · | · | 10,891 Direct | · | Acquired | (price as of 2026-10-06) |
| June 10, 2026 | PCRX | A | 6,405 | · | · | 26,541 Direct | +31.81% | Acquired | (price as of 2026-10-06) |
| March 17, 2026 | PCRX | S | 500 | $21.81 | $10,905 | 20,136 Direct | -2.42% | Disposed | 13.5% (price as of 2026-10-06) |
| June 11, 2025 | PCRX | A | 6,163 | · | · | 20,636 Direct | +42.58% | Acquired | (price as of 2026-10-06) |
| June 11, 2025 | PCRX | A | 11,279 | · | · | 11,279 Direct | · | Acquired | (price as of 2026-10-06) |
| Aug. 12, 2024 | PCRX | P | 1,400 | $11.58 | $16,212 | 14,473 Direct | +10.71% | Acquired | 113.8% (price as of 2026-10-06) |
| June 12, 2024 | PCRX | A | 5,230 | · | · | 13,073 Direct | +66.68% | Acquired | (price as of 2026-10-06) |
| June 12, 2024 | PCRX | A | 12,179 | · | · | 12,179 Direct | · | Acquired | (price as of 2026-10-06) |
| June 14, 2023 | PCRX | A | 12,925 | · | · | 12,925 Direct | · | Acquired | (price as of 2026-10-06) |
| June 14, 2023 | PCRX | A | 1,775 | · | · | 7,843 Direct | +29.25% | Acquired | (price as of 2026-10-06) |
| June 8, 2022 | PCRX | A | 8,225 | · | · | 8,225 Direct | · | Acquired | (price as of 2026-10-06) |
| June 8, 2022 | PCRX | A | 1,160 | · | · | 6,068 Direct | +23.63% | Acquired | (price as of 2026-10-06) |
| May 9, 2022 | PCRX | S | 1,000 | $59.37 | $59,370 | 4,908 Direct | -16.93% | Disposed | -58.3% (price as of 2026-10-06) |
| Dec. 17, 2021 | PCRX | G | 400 | · | · | 5,908 Direct | -6.34% | Disposed | (price as of 2026-10-06) |
| June 9, 2021 | PCRX | A | 1,066 | · | · | 6,308 Direct | +20.34% | Acquired | (price as of 2026-10-06) |
| June 9, 2021 | PCRX | A | 7,626 | · | · | 7,626 Direct | · | Acquired | (price as of 2026-10-06) |
| March 15, 2021 | PCRX | S | 734 | $72.26 | $53,039 | 5,242 Direct | -12.28% | Disposed | -65.7% (price as of 2026-10-06) |
| June 9, 2020 | PCRX | A | 8,027 | · | · | 8,027 Direct | · | Acquired | (price as of 2026-10-06) |
| June 9, 2020 | PCRX | A | 1,260 | · | · | 5,976 Direct | +26.72% | Acquired | (price as of 2026-10-06) |
| Dec. 16, 2019 | PCRX | G | 300 | · | · | 4,716 Direct | -5.98% | Disposed | (price as of 2026-10-06) |
| June 5, 2019 | PCRX | A | 8,437 | · | · | 8,437 Direct | · | Acquired | (price as of 2026-10-06) |
| June 5, 2019 | PCRX | A | 4,134 | · | · | 5,016 Direct | +468.71% | Acquired | (price as of 2026-10-06) |
| June 13, 2018 | PCRX | A | 4,693 | · | · | 4,693 Direct | · | Acquired | (price as of 2026-10-06) |
| June 13, 2018 | PCRX | A | 782 | · | · | 882 Direct | +782.00% | Acquired | (price as of 2026-10-06) |
| Aug. 8, 2017 | PCRX | P | 100 | $37.13 | $3,713 | 100 Direct | · | Acquired | -33.3% (price as of 2026-10-06) |
| June 14, 2017 | PCRX | A | 8,144 | · | · | 8,144 Direct | · | Acquired | (price as of 2026-10-06) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 10, 2026 | PCRX | Stock Option (Right to Buy) | Common Stock | $23.42 | June 10, 2036 | 10,891 | Acquired |
| June 11, 2025 | PCRX | Stock Option (Right to Buy) | Common Stock | $24.34 | June 11, 2035 | 11,279 | Acquired |
| June 12, 2024 | PCRX | Stock Option (Right to Buy) | Common Stock | $28.68 | June 12, 2034 | 12,179 | Acquired |
| June 14, 2023 | PCRX | Stock Option (Right to Buy) | Common Stock | $38.74 | June 14, 2033 | 12,925 | Acquired |
| June 8, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock | $59.39 | June 8, 2032 | 8,225 | Acquired |
| June 9, 2021 | PCRX | Stock Option (Right to Buy) | Common Stock | $60.96 | June 9, 2031 | 7,626 | Acquired |
| June 9, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock | $47.65 | June 9, 2030 | 8,027 | Acquired |
| June 5, 2019 | PCRX | Stock Option (Right to Buy) | Common Stock | $43.54 | June 5, 2029 | 8,437 | Acquired |
| June 13, 2018 | PCRX | Stock Option (Right to Buy) | Common Stock | $38.35 | June 13, 2028 | 4,693 | Acquired |
| June 14, 2017 | PCRX | Stock Option (Right to Buy) | Common Stock | $44.20 | June 14, 2027 | 8,144 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).